BusinessVBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901By Nasdaq OMXJan 17, 2018, 1:00 PM UTC
BusinessVBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare ConferenceBy Nasdaq OMXDec 12, 2017, 1:00 PM UTC
BusinessVBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017By Nasdaq OMXNov 10, 2017, 1:00 PM UTC
